Mark de Souza
President and CEO
Mark has over 20 years of executive and entrepreneurial experience in the rare disease space at multiple venture backed companies. He held positions of increasing responsibility in business development (culminating as VP) at Dyax Corp, which was acquired by Shire for its FDA-approved drugs for hereditary angioedema. He has been a founder, CEO, or Executive Chair of Lotus Tissue Repair (a Third Rock Ventures company acquired by Shire), PellePharm and Molecular Skin Therapeutics (both BridgeBio companies), SeylanMed and Chromaderm (both merged into Dermbiont), NFlection Therapeutics, and Phoenicis Therapeutics. Mark is a board member of SNAPkids, a San Francisco Bay Area non-profit organization, and an advisor to the CureGM1 Foundation.
Mark has over 20 years of executive and entrepreneurial experience in the rare disease space at multiple venture backed companies. He held positions of increasing responsibility in business development (culminating as VP) at Dyax Corp, which was acquired by Shire for its FDA-approved drugs for hereditary angioedema. He has been a founder, CEO, or Executive Chair of Lotus Tissue Repair (a Third Rock Ventures company acquired by Shire), PellePharm and Molecular Skin Therapeutics (both BridgeBio companies), SeylanMed and Chromaderm (both merged into Dermbiont), NFlection Therapeutics, and Phoenicis Therapeutics. Mark is a board member of SNAPkids, a San Francisco Bay Area non-profit organization, and an advisor to the CureGM1 Foundation.